GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0015980111 | Thyroid | PTC | energy derivation by oxidation of organic compounds | 176/5968 | 318/18723 | 2.67e-18 | 2.90e-16 | 176 |
GO:0072331113 | Thyroid | PTC | signal transduction by p53 class mediator | 92/5968 | 163/18723 | 7.29e-11 | 2.54e-09 | 92 |
GO:1901796113 | Thyroid | PTC | regulation of signal transduction by p53 class mediator | 58/5968 | 93/18723 | 1.38e-09 | 3.95e-08 | 58 |
GO:0072332113 | Thyroid | PTC | intrinsic apoptotic signaling pathway by p53 class mediator | 48/5968 | 76/18723 | 1.99e-08 | 4.61e-07 | 48 |
GO:001810518 | Thyroid | PTC | peptidyl-serine phosphorylation | 143/5968 | 315/18723 | 2.94e-07 | 5.04e-06 | 143 |
GO:0042771112 | Thyroid | PTC | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 30/5968 | 43/18723 | 3.79e-07 | 6.32e-06 | 30 |
GO:001820916 | Thyroid | PTC | peptidyl-serine modification | 151/5968 | 338/18723 | 4.61e-07 | 7.51e-06 | 151 |
GO:001821017 | Thyroid | PTC | peptidyl-threonine modification | 66/5968 | 125/18723 | 9.50e-07 | 1.43e-05 | 66 |
GO:0043467110 | Thyroid | PTC | regulation of generation of precursor metabolites and energy | 68/5968 | 130/18723 | 1.03e-06 | 1.52e-05 | 68 |
GO:001810717 | Thyroid | PTC | peptidyl-threonine phosphorylation | 62/5968 | 116/18723 | 1.16e-06 | 1.69e-05 | 62 |
GO:0008630112 | Thyroid | PTC | intrinsic apoptotic signaling pathway in response to DNA damage | 54/5968 | 99/18723 | 2.46e-06 | 3.22e-05 | 54 |
GO:001931810 | Thyroid | PTC | hexose metabolic process | 108/5968 | 237/18723 | 6.42e-06 | 7.65e-05 | 108 |
GO:000599614 | Thyroid | PTC | monosaccharide metabolic process | 115/5968 | 257/18723 | 9.36e-06 | 1.05e-04 | 115 |
GO:000600615 | Thyroid | PTC | glucose metabolic process | 90/5968 | 196/18723 | 2.54e-05 | 2.50e-04 | 90 |
GO:00061097 | Thyroid | PTC | regulation of carbohydrate metabolic process | 75/5968 | 178/18723 | 2.44e-03 | 1.27e-02 | 75 |
GO:00182126 | Thyroid | PTC | peptidyl-tyrosine modification | 142/5968 | 378/18723 | 1.02e-02 | 4.14e-02 | 142 |
GO:00328851 | Thyroid | PTC | regulation of polysaccharide biosynthetic process | 19/5968 | 37/18723 | 1.07e-02 | 4.29e-02 | 19 |
GO:00109066 | Thyroid | PTC | regulation of glucose metabolic process | 50/5968 | 119/18723 | 1.25e-02 | 4.88e-02 | 50 |
GO:009719335 | Thyroid | ATC | intrinsic apoptotic signaling pathway | 171/6293 | 288/18723 | 1.86e-19 | 2.67e-17 | 171 |
GO:000609134 | Thyroid | ATC | generation of precursor metabolites and energy | 256/6293 | 490/18723 | 6.55e-18 | 7.69e-16 | 256 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK2 | SNV | Missense_Mutation | | c.1133G>T | p.Arg378Leu | p.R378L | Q92630 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
DYRK2 | SNV | Missense_Mutation | rs773264334 | c.1592N>A | p.Arg531Gln | p.R531Q | Q92630 | protein_coding | tolerated(0.15) | probably_damaging(0.964) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | | c.1520T>C | p.Leu507Pro | p.L507P | Q92630 | protein_coding | deleterious(0.02) | possibly_damaging(0.899) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | rs756215589 | c.70N>T | p.Val24Phe | p.V24F | Q92630 | protein_coding | tolerated_low_confidence(0.21) | benign(0.011) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DYRK2 | SNV | Missense_Mutation | | c.271N>G | p.Gln91Glu | p.Q91E | Q92630 | protein_coding | tolerated_low_confidence(0.61) | benign(0.003) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DYRK2 | insertion | In_Frame_Ins | novel | c.1766_1767insAGATATAGAAGATGGTCGTTTCTTGTCAGTCTCGTTAGTTTTAGT | p.Asn589delinsLysAspIleGluAspGlyArgPheLeuSerValSerLeuValLeuVal | p.N589delinsKDIEDGRFLSVSLVLV | Q92630 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | novel | c.610N>C | p.Asp204His | p.D204H | Q92630 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | rs748801595 | c.1447N>T | p.Arg483Trp | p.R483W | Q92630 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | novel | c.1210N>C | p.Asp404His | p.D404H | Q92630 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
DYRK2 | SNV | Missense_Mutation | | c.563N>T | p.Ala188Val | p.A188V | Q92630 | protein_coding | deleterious(0.01) | probably_damaging(0.942) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme21Left | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565847 | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565807 | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme16DMAT | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | HARMINE | HARMINE | 22998443 |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | LEUCETTAMINE B | LEUCETTAMINE B | 22998443 |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | HARMINE | HARMINE | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme14BINDY | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565851 | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme21Right | | |